Results 71 to 80 of about 11,769 (205)

Personalised Perception: The Effect of Personality on the Sensory Effects of Psychedelics

open access: yesDrug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Psychedelics induce a wide range of sensory distortions and hallucinations (henceforth ‘distortions’). Yet, little is known about factors that influence the occurrence of certain distortions. Extra‐pharmacological variables including personality traits have been found to correlate with the occurrence of different subjective ...
Alexander Boardman   +2 more
wiley   +1 more source

Accuracy of Patient‐Reported Exposure to New Psychoactive Substances and Other Illicit Drugs in Australian Emergency Departments: Findings From the Emerging Drugs Network of Australia

open access: yesDrug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction New psychoactive substances (NPS) present a unique challenge in clinical, public health and drug‐policy contexts. Continued diversity, unknown potency and often unintentional exposure can limit the accuracy of self‐reported data.
Marjan J. Nijmeijer   +13 more
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström   +10 more
wiley   +1 more source

Distinct Prescription Patterns Emerge Years Before ALS Diagnosis: A Nationwide Registry‐Based Study

open access: yesAnnals of Neurology, Volume 99, Issue 6, Page 1516-1525, June 2026.
Objective The prodromal phase of amyotrophic lateral sclerosis (ALS) is poorly defined. We aimed to characterize prescription drug use patterns in the pre‐diagnostic period by analyzing nationwide prescription data to identify the earliest divergence between individuals who developed ALS and matched healthy controls.
Magne Haugland Solheim   +6 more
wiley   +1 more source

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 6, Page 1595-1606, June 2026.
Abstract Aims Cannabidiol (CBD), the main non‐intoxicating compound from the cannabis plant, is regularly used by patients with chronic pain who also take analgesics. CBD has previously been shown to inhibit CYP‐mediated drug metabolism. This study aimed to characterize the potential pharmacokinetic interaction of CBD with amitriptyline and tramadol ...
Andriy A. Gorbenko   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy